
|Articles|December 15, 2005
Intravitreal anti-VEGF drugs are step forward in AMD management
The promise of 2004, that new anti-vascular endothelial growth factor (VEGF) treatments for age-related macular degeneration (AMD) be developed, came to fruition in 2005, much to the excitement of ophthalmologists. These emerging treatments for AMD took center stage this year and resulted in numerous ideas about the effect of the pharmaceutical advancements and their impact on other retinal diseases.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases
2
Kodiak Sciences releases follow-up, 20-week data from APEX study
3
From then to next: Five decades of transformation in ophthalmology
4
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
5


















































.png)


